Publications

Search
Found 13 results
Filters: Author is Soumerai, S.B.  [Clear All Filters]
2009
Law M, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Archives of Internal MedicineArch.Intern.Med.. 2009;169(21):1969-1974.
Law M, Soumerai SB, Adams AS, Majumdar SR. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Archives of internal medicine. 2009;169(21):1969.
2008
Law M, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ (Clinical research ed.)BMJ. 2008;337:a1055.
Law M, Majumdar SR, Soumerai SB. Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study. BMJ: British Medical Journal. 2008;337.
Law M, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatric services (Washington, D.C.)Psychiatr.Serv.. 2008;59(5):540-546.
Law M, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. The Journal of clinical psychiatry. 2008;69(1):47.
Law M, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. The Journal of clinical psychiatryJ.Clin.Psychiatry. 2008;69(1):47-53.
Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law M, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs. 2008;27(3):w185-w195.
Soumerai SB, Zhang F, Ross-Degnan D, Ball DE, LeCates RF, Law M, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health affairs (Project Hope)Health.Aff.(Millwood). 2008;27(3):w185-95.